Posted by: Chris Maloney | January 29, 2013

Antimalarial Emerging Treatments: Homeopathics?

P. berghei parasites in blood capillaries of t...

P. berghei parasites in blood capillaries of the lungs, spleen and adipose tissue in a live mouse. Visualisation is performed by measuring bioluminescence (green/yellow) of transgenic parasites expressing the bioluminescent reporter protein Luciferase (Photo credit: Wikipedia)

One of the ongoing issues of malaria is drug resistance.  In an animal trial, a homeopathic nosode (diluted to below the molecular level) of malaria more than doubled the lifespan of mice injected with malaria.

Understanding that we often have no effective drugs for resistant strains, only politics keeps human trials from taking place.  That, and the fact that a single vial of homeopathic nosode could treat an entire subcontinent (where’s the profit margin?).  Here’s the animal trial.

J Vector Borne Dis. 2012 Jun;49(2):72-7.

Antimalarial potential of Nosode 30 and 200 against Plasmodium berghei infection in BALB/c mice.

Bagai U, Rajan A, Kaur S.


Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, India.



OBJECTIVES: Homeopathy is considered as an emerging area of alternative medicine which could be established for the global health care. One of the greatest objections to this science lies in its inability to explain the

mechanism of action of the micro doses based on scientific experiments and proofs. The present study has been undertaken to screen in vivo antimalarial activity of Malaria Co Nosode 30 and Nosode 200 against Plasmodium berghei infection in BALB/c mice. METHODS: Peter’s 4-day test was used to evaluate the in vivo schizontocidal effect of Nosode 30 and Nosode 200. One month follow-up study was done to calculate the mean survival time of mice in each group. Biochemical analysis was carried out to assess the liver and kidney function tests using diagnostic kits. RESULTS: Nosode 30 and 200 exhibited 87.02 and 37.97% chemosuppression on Day 7 and mean survival time (MST) of 18.5 ± 2.16 and 16.5 ± 1.37 days respectively, which were extremely statistically significant when compared to MST of infected control (8.55 ± 0.83 days). The safety of Nosode 30 was also confirmed by the comparable levels of ALP, SGOT, SGPT activities, concentration of bilirubin, urea and creatinine to CQ treated group. CONCLUSION: Nosode 30 possesses considerable in vivo antiplasmodial activity against P. berghei infection as compared to Nosode 200 as evident from the chemosuppression obtained using Peter’s 4-day test. Further, studies on the drug can be carried out to establish its antimalarial potential in monotherapy or in combination with other homeopathic drug formulations.


Tell me what you think!

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s


%d bloggers like this: